SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories soars on getting USFDA nod for oral solid dosage formulations facilities

20 Jul 2012 Evaluate

Ipca Laboratories is currently trading at Rs. 388.00, up by 14.50 points or 3.88% from its previous closing of Rs. 373.50 on the BSE.

The scrip opened at Rs. 373.00 and has touched a high and low of Rs. 400.80 and Rs. 372.00 respectively. So far 112890 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 400.80 on 20-Jul-2012 and a 52 week low of Rs. 230.20 on 04-Oct-2011.

Last one week high and low of the scrip stood at Rs. 400.80 and Rs. 371.10 respectively. The current market cap of the company is Rs. 5013.22 crore.

The promoters holding in the company stood at 46.01% while Institutions and Non-Institutions held 31.59% and 22.40% respectively.

Ipca Laboratories has received the US Food and Drug Administration (USFDA) approval for its oral solid dosage formulations manufacturing facility situated at Pharmazone, SEZ Indore, Pithampur in Madhya Pradesh. This approval will enable the company to commercialize more oral solid dosage formulations in the US market.

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.

Ipca Laboratories Share Price

1543.95 13.35 (0.87%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.75
Dr. Reddys Lab 1270.95
Cipla 1333.55
Zydus Lifesciences 911.85
Lupin 2343.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×